Total Payments
$206,495
2024 Payments
$3,068
Companies
37
Transactions
659
Medicare Patients
7,507
Medicare Billing
$633,036
Payment Breakdown by Category
Other$143,229 (69.4%)
Consulting$33,818 (16.4%)
Food & Beverage$20,232 (9.8%)
Travel$9,090 (4.4%)
Education$126.56 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $141,130 | 73 | 68.3% |
| Consulting Fee | $33,818 | 18 | 16.4% |
| Food and Beverage | $20,232 | 538 | 9.8% |
| Travel and Lodging | $9,090 | 23 | 4.4% |
| Compensation for serving as faculty or as a speaker for a medical education program | $2,000 | 1 | 1.0% |
| Education | $126.56 | 5 | 0.1% |
| Debt forgiveness | $98.85 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $84,577 | 125 | $0 (2024) |
| Gilead Sciences, Inc. | $54,110 | 39 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $20,590 | 64 | $0 (2024) |
| Lilly USA, LLC | $11,585 | 12 | $0 (2024) |
| Medtronic, Inc. | $10,603 | 11 | $0 (2023) |
| PORTOLA PHARMACEUTICALS, INC. | $7,568 | 9 | $0 (2019) |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $5,355 | 13 | $0 (2021) |
| Boston Scientific Corporation | $2,206 | 47 | $0 (2024) |
| Medtronic Vascular, Inc. | $1,620 | 14 | $0 (2020) |
| Amgen Inc. | $1,316 | 47 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,068 | 98 | AstraZeneca Pharmaceuticals LP ($346.99) |
| 2023 | $3,680 | 80 | Medtronic, Inc. ($1,688) |
| 2022 | $7,101 | 74 | Medtronic, Inc. ($5,375) |
| 2021 | $20,810 | 82 | AstraZeneca Pharmaceuticals LP ($9,434) |
| 2020 | $40,355 | 74 | Boehringer Ingelheim Pharmaceuticals, Inc. ($21,888) |
| 2019 | $35,997 | 92 | Boehringer Ingelheim Pharmaceuticals, Inc. ($29,718) |
| 2018 | $49,395 | 91 | Boehringer Ingelheim Pharmaceuticals, Inc. ($21,081) |
| 2017 | $46,088 | 68 | Gilead Sciences Inc ($28,913) |
All Payment Transactions
659 individual payment records from CMS Open Payments — Page 1 of 27
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $27.46 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 12/17/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $17.21 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 12/16/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $26.28 | General |
| Category: Cardiology | ||||||
| 12/09/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $24.95 | General |
| Category: Cardiovascular | ||||||
| 11/26/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $25.38 | General |
| Category: Cardiology | ||||||
| 11/18/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $24.85 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/18/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $21.41 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/13/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: DIABETES | ||||||
| 11/06/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $24.72 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 11/06/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $17.99 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/04/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $13.13 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 10/31/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $2.65 | General |
| Category: Not Applicable | ||||||
| 10/30/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $24.71 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 10/28/2024 | Lexicon Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $24.79 | General |
| 10/25/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $5.05 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 10/23/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $22.41 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/22/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $22.79 | General |
| Category: Cardiology | ||||||
| 10/21/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $30.50 | General |
| Category: Cardiology | ||||||
| 10/17/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $25.28 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/11/2024 | Celgene Corporation | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $20.78 | General |
| Category: Cardiovascular | ||||||
| 10/08/2024 | Abbott Laboratories | JOT DX (Device) | Food and Beverage | In-kind items and services | $53.82 | General |
| Category: Cardiac Rhythm Management | ||||||
| 09/25/2024 | Boston Scientific Corporation | WATCHMAN FLX (Device) | Food and Beverage | In-kind items and services | $23.78 | General |
| Category: WATCHMAN FLX_IC | ||||||
| 09/18/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $22.50 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 09/18/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $4.45 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 09/12/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $22.77 | General |
| Category: Cardiovascular and Metabolism | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 18 | 2,453 | 3,676 | $1.6M | $181,277 |
| 2022 | 21 | 1,615 | 2,401 | $1.2M | $142,507 |
| 2021 | 18 | 1,689 | 2,674 | $1.3M | $174,818 |
| 2020 | 22 | 1,750 | 2,385 | $930,327 | $134,433 |
Total Patients
7,507
Total Services
11,136
Medicare Billing
$633,036
Procedure Codes
84
All Medicare Procedures & Services
84 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 313 | 559 | $363,350 | $60,167 | 16.6% |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | Office | 2023 | 34 | 68 | $22,440 | $17,375 | 77.4% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 39 | 39 | $174,948 | $15,981 | 9.1% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 90 | 90 | $269,130 | $15,422 | 5.7% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 191 | 194 | $144,700 | $11,666 | 8.1% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 989 | 1,478 | $103,460 | $10,963 | 10.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 36 | 96 | $63,105 | $10,455 | 16.6% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 347 | 605 | $158,940 | $7,751 | 4.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 61 | 63 | $72,441 | $7,666 | 10.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 55 | 55 | $63,860 | $7,241 | 11.3% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 35 | 140 | $27,300 | $5,918 | 21.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 24 | 41 | $21,935 | $3,014 | 13.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 15 | 15 | $16,425 | $2,369 | 14.4% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 41 | 41 | $45,195 | $2,317 | 5.1% |
| 93248 | Heart rhythm review and interpretation of continous external ekg over 8-15 days | Office | 2023 | 60 | 61 | $9,105 | $1,378 | 15.1% |
| 93246 | Heart rhythm recording of continous external ekg over 8-15 days | Office | 2023 | 57 | 58 | $5,470 | $680.51 | 12.4% |
| 93228 | Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | Office | 2023 | 23 | 23 | $7,575 | $451.06 | 6.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 32 | 39 | $1,991 | $327.60 | 16.5% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Facility | 2023 | 11 | 11 | $1,645 | $137.17 | 8.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 291 | 500 | $325,000 | $53,678 | 16.5% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2022 | 37 | 37 | $141,032 | $16,584 | 11.8% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 64 | 64 | $168,640 | $11,001 | 6.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 34 | 90 | $51,750 | $8,601 | 16.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 52 | 52 | $61,100 | $7,379 | 12.1% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 345 | 567 | $133,245 | $7,298 | 5.5% |
About Dr. Jonathan Bradlow, MD
Dr. Jonathan Bradlow, MD is a Cardiovascular Disease healthcare provider based in Bronx, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1013014836.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jonathan Bradlow, MD has received a total of $206,495 in payments from pharmaceutical and medical device companies, with $3,068 received in 2024. These payments were reported across 659 transactions from 37 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($141,130).
As a Medicare-enrolled provider, Bradlow has provided services to 7,507 Medicare beneficiaries, totaling 11,136 services with total Medicare billing of $633,036. Data is available for 4 years (2020–2023), covering 84 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Bronx, NY
- Active Since 09/20/2006
- Last Updated 03/29/2013
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1013014836
Products in Payments
- JARDIANCE (Drug) $95,880
- Ranexa (Drug) $47,596
- FARXIGA (Drug) $19,860
- BEVYXXA (Drug) $7,545
- Veklury (Drug) $6,470
- LifeVest (Device) $5,355
- CoreValve Evolut (Device) $3,950
- COREVALVE EVOLUT R (Device) $3,750
- ELIQUIS (Drug) $1,221
- Repatha (Biological) $1,152
- WATCHMAN (Device) $984.38
- ENTRESTO (Drug) $836.55
- GENERAL THERAPIES (Device) $780.17
- VERQUVO (Drug) $711.54
- BRILINTA (Drug) $536.23
- XARELTO (Drug) $514.69
- WATCHMAN FLX (Device) $382.87
- PACEART SYSTEM ECG MODULE (Device) $375.00
- LEQVIO (Drug) $373.11
- MULTAQ (Drug) $282.09
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Bronx
Joseph Helft, Md, MD
Cardiovascular Disease — Payments: $747,257
Cardiovascular Disease $747,257
Luigi Di Biase, Md, Phd, MD, PHD
Cardiovascular Disease — Payments: $726,082
Cardiovascular Disease $726,082
Timothy Vittorio, M.d, M.D
Cardiovascular Disease — Payments: $63,032
Cardiovascular Disease $63,032
Jil Tardiff, Md, MD
Cardiovascular Disease — Payments: $53,201
Cardiovascular Disease $53,201
Adam Splaver, Md, MD
Cardiovascular Disease — Payments: $43,803
Cardiovascular Disease $43,803
Andrew Krumerman, Md, MD
Cardiovascular Disease — Payments: $42,534
Cardiovascular Disease $42,534